Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Paclitaxel | Approved | Phase 4 | 112 | 45 | 125 | 503 | 3 | US | Jan 7, 2005 | 1994-02 |
| Pembrolizumab | Approved | Phase 3 | 112 | 58 | 19 | 221 | 3 | US | Sep 4, 2014 | Aug 26, 2010 |
| Trastuzumab | Approved | Phase 4 | 96 | 37 | 109 | 488 | 4 | EU, US | Sep 25, 1998 | 1998-04 |
| Fulvestrant | Approved | Phase 4 | 82 | 41 | 48 | 241 | 12 | EU, US | Apr 25, 2002 | 1997-05 |
| Capecitabine | Approved | Phase 4 | 73 | 44 | 92 | 309 | 2 | US | Apr 30, 1998 | 1998-07 |
| Pertuzumab | Approved | Phase 4 | 70 | 26 | 39 | 152 | 6 | EU, US | Jun 8, 2012 | 2003-02 |
| Letrozole | Approved | Phase 4 | 59 | 27 | 64 | 235 | 3 | US | Jul 25, 1997 | 1998-03 |
| Docetaxel | Approved | Phase 4 | 51 | 27 | 107 | 353 | 8 | US | May 14, 1996 | 1993-05 |
| Palbociclib | Approved | Phase 4 | 42 | 12 | 11 | 113 | 8 | EU, US | Feb 3, 2015 | Sep 15, 2008 |
| Abemaciclib | Approved | Phase 4 | 42 | 27 | 7 | 73 | 5 | EU, US | Sep 28, 2017 | Jul 31, 2012 |
| Sacituzumab Govitecan | Approved | Phase 3 | 41 | 21 | 12 | 52 | 4 | EU, US | Apr 22, 2020 | Dec 17, 2012 |
| Doxorubicin | Approved | Phase 4 | 37 | 16 | 65 | 249 | 2 | EU, US | Dec 23, 1987 | 1989-05 |
| Tamoxifen | Approved | Phase 4 | 35 | 19 | 93 | 201 | 3 | US | Oct 29, 2005 | 1987-09 |
| Anastrozole | Approved | Phase 4 | 34 | 16 | 50 | 146 | 3 | US | Dec 27, 1995 | 1996-01 |
| Olaparib | Approved | Phase 4 | 34 | 16 | 5 | 66 | 2 | US | Aug 17, 2017 | Jul 8, 2008 |
| Ribociclib | Approved | Phase 4 | 34 | 18 | 14 | 63 | 3 | EU, US | Mar 13, 2017 | Sep 6, 2013 |
| Eribulin | Approved | Phase 4 | 29 | 11 | 22 | 96 | 1 | US | Nov 15, 2010 | Sep 20, 2006 |
| Gemcitabine | Approved | Phase 3 | 28 | 15 | 40 | 143 | 3 | US | Aug 4, 2011 | 1997-08 |
| Exemestane | Approved | Phase 4 | 26 | 14 | 48 | 127 | 2 | US | Oct 21, 1999 | 1996-05 |
| Epirubicin | Approved | Phase 4 | 25 | 13 | 69 | 153 | 1 | US | Sep 15, 1999 | 1991-10 |
| Trastuzumab Emtansine | Approved | Phase 4 | 25 | 10 | 26 | 88 | 3 | EU, US | Feb 22, 2013 | 2006-04 |
| Tucatinib | Approved | Phase 4 | 21 | 8 | 4 | 32 | 2 | EU, US | Apr 17, 2020 | Feb 28, 2014 |
| Datopotamab Deruxtecan | Approved | Phase 3 | 18 | 9 | 6 | 18 | 3 | EU, US | Jan 17, 2025 | Mar 1, 2010 |
| Everolimus | Approved | Phase 3 | 16 | 8 | 14 | 76 | 2 | US | Mar 30, 2009 | May 10, 2005 |
| Alpelisib | Approved | Phase 4 | 15 | 3 | 7 | 36 | 2 | EU, US | May 24, 2019 | 2011-08 |
| Elacestrant | Approved | Phase 3 | 14 | 12 | 5 | 21 | 2 | EU, US | Jan 27, 2023 | Apr 1, 2016 |
| Inavolisib | Approved | Phase 3 | 13 | 9 | 4 | 14 | 2 | EU, US | Oct 10, 2024 | Dec 13, 2016 |
| Goserelin | Approved | Phase 4 | 12 | 8 | 29 | 75 | 1 | US | Dec 29, 1989 | 1987-09 |
| Capivasertib | Approved | Phase 3 | 11 | 3 | 4 | 17 | 2 | EU, US | Nov 16, 2023 | 2014-01 |
| Neratinib | Approved | Phase 3 | 10 | 8 | 1 | 34 | 3 | EU, US | Jul 17, 2017 | Apr 4, 2007 |
| Talazoparib | Approved | Phase 2 | 7 | 4 | 0 | 22 | 2 | US | Oct 16, 2018 | Feb 4, 2014 |
| Camizestrant | Approved | Phase 3 | 6 | 4 | 3 | 6 | 1 | US | Sep 4, 2026 | Nov 12, 2020 |
| Trastuzumab Deruxtecan | Approved | Phase 3 | 6 | 2 | 1 | 6 | 6 | US | Dec 20, 2019 | Nov 12, 2020 |
| Fluorouracil | Approved | Phase 3 | 5 | 2 | 51 | 96 | 1 | US | Feb 20, 2026 | 1989-05 |
| Imlunestrant | Approved | Phase 2 | 4 | 3 | 0 | 5 | 2 | EU, US | Sep 25, 2025 | Dec 10, 2019 |
| Methotrexate | Approved | Phase 3 | 3 | 2 | 23 | 46 | 1 | US | Aug 10, 1959 | 1990-12 |
| Denosumab | Approved | Phase 4 | 3 | 0 | 5 | 18 | 6 | US | Jun 1, 2010 | 2004-09 |
| Lapatinib | Approved | Phase 3 | 1 | 0 | 13 | 82 | 2 | EU, US | Mar 13, 2007 | 2004-03 |
| Toremifene | Approved | Phase 4 | 1 | 1 | 5 | 8 | 2 | EU, US | Feb 14, 1996 | 1993-05 |
| Margetuximab | Approved | Phase 2 | 1 | 0 | 0 | 4 | 1 | US | Dec 16, 2020 | 2010-07 |
| Thiotepa | Approved | Phase 3 | 0 | 0 | 7 | 25 | 2 | US | Jan 26, 2017 | 1991-12 |
| Megestrol | Approved | Phase 3 | 0 | 0 | 2 | 6 | 1 | US | Aug 8, 1988 | 1987-12 |
| Trastuzumab Deruxtecan | Approved | — | 0 | 0 | 0 | 0 | 6 | US | Dec 20, 2019 | — |
| Carboplatin | Phase 4 | Phase 4 | 88 | 40 | 47 | 267 | 0 | — | — | 1991-11 |
| Cyclophosphamide | Phase 4 | Phase 4 | 79 | 41 | 135 | 456 | 0 | — | — | 1989-05 |
| Nab-paclitaxel | Phase 4 | Phase 4 | 51 | 24 | 32 | 151 | 0 | — | — | Jun 1, 2004 |
| Pyrotinib | Phase 4 | Phase 4 | 29 | 13 | 9 | 58 | 0 | — | — | 2013-01 |
| Bevacizumab | Phase 4 | Phase 4 | 20 | 16 | 22 | 158 | 0 | — | — | 2000-11 |
| Chemotherapy | Phase 4 | Phase 4 | 20 | 9 | 15 | 50 | 0 | — | — | 1999-01 |
| Toripalimab | Phase 4 | Phase 4 | 13 | 10 | 1 | 19 | 0 | — | — | Dec 21, 2018 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.